The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
B | Blood and blood forming organs | |
2
|
B02 | Antihemorrhagics | |
3
|
B02A | Antifibrinolytics | |
4
|
B02AA | Amino acids |
| Code | Title | |
|---|---|---|
| B02AA01 | Aminocaproic acid | |
| B02AA02 | Tranexamic acid | |
| B02AA03 | Aminomethylbenzoic acid |
| Active Ingredient |
|---|
|
Aminocaproic acid is 6-aminohexanoic acid, which acts as an inhibitor of fibrinolysis. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. |
|
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. |
| Document | Type | Information Source | |
|---|---|---|---|
| AZEPTIL Capsule | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| AZEPTIL Solution for injection | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| CYKLOKAPRON Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |